TRTMNT INTRUPTN AMNG SBJTS ON POTENT ANTIRTROVIRAL THRPY W/IN 16 DYS OF DIAGNSS

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目及 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 这项研究的主要目的是测试一种疫苗，看看它是否能抵抗艾滋病毒感染。该研究疫苗是为那些在感染艾滋病毒后不久就开始使用抗艾滋病毒药物的人提供的。我们正在寻找几周前（急性感染）或几个月前（最近感染）感染的人。 这项研究的第一个目标是观察如果受试者接受研究疫苗，然后停止服用抗HIV药物，他们血液中的HIV数量会发生什么变化。我们还不知道研究疫苗是否会对血液中的HIV数量产生影响。这项研究的第二个目标是观察研究疫苗对艾滋病毒感染者是否安全。如果研究疫苗起作用，接受疫苗的人可能会服用更少的抗HIV药物。 疫苗帮助人体的免疫系统对抗艾滋病毒等感染。参加本研究的人将接受含有研究疫苗或疫苗安慰剂的注射（注射）。这项研究的安慰剂是一种水和盐的溶液，没有疫苗，药物或药物。我们将观察接受研究疫苗或安慰剂的人的免疫系统反应是否不同。 我们将通过比较接受疫苗或安慰剂的人血液中HIV的数量（HIV病毒载量）来研究免疫系统，然后停止服用抗HIV药物24周，大约6个月。许多人（但不是所有人）将接受本研究所述的研究疫苗或安慰剂。这项研究中的许多人，但不是所有人，将能够停止他们的抗艾滋病毒药物24周。那些既能接种疫苗又能停止使用抗艾滋病毒药物的人将接受病毒载量的测量。研究疫苗或安慰剂将通过注射（注射）在靠近肩膀的一个上臂给予人们。安慰剂与研究疫苗相似，但不含活性物质。研究疫苗被称为MRKAd 5 HIV-1 gag/pol/nef疫苗。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The main purpose of this study is to test a vaccine to see if it fights HIV infection. The study vaccine is for people who started anti-HIV drugs soon after they were infected with HIV. We are looking for people who were infected just a few weeks ago (acute infection) or a few months ago (recent infection). The first goal of this study is to see what happens to the amount of HIV in subjects' blood if they receive the study vaccine and then stop taking their anti-HIV drugs. We do not yet know if the study vaccine will make a difference on the amount of HIV in the blood. The second goal of the study is to see if the study vaccine is safe for people who have HIV. If the study vaccine works, people who receive it may be able to take fewer anti-HIV drugs. Vaccines help the body's immune system fight infections such as HIV. People who join this study will receive injections (shots) that contain either the study vaccine or a vaccine placebo. The placebo for this study is a water and salt solution that has no vaccine, medicine, or drugs. We will see if the immune system responds differently in people who receive the study vaccine or the placebo. We will study the immune system by comparing the amount of HIV in the blood (HIV viral load) in people who receive either the vaccine or the placebo and who then stop taking their anti-HIV drugs for 24 weeks, about six months. Many people, but not all, will receive either the study vaccine or placebo as described for this study. Many people on this study, but not all, will be able to stop their anti-HIV drugs for 24 weeks. Those who can both receive the vaccine and stop their anti-HIV drugs will have their viral load measured. The study vaccine or placebo will be given to people by injections (shots) in one upper arm near the shoulder. The placebo is like the study vaccine but without the active material. The study vaccine is called MRKAd5 HIV-1 gag/pol/nef vaccine.